BofA analyst Craig Bijou lowered the firm’s price target on Merit Medical (MMSI) to $80 from $100 and keeps a Neutral rating on the shares. While the Q1 beat did not fully flow through, Merit said it typically does not update guidance in Q1, but feels confident and intends to the review guidance at Q2, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Analyst Reiterates Buy on Merit Medical Systems as Strong Q1 Results and Cash Generation Offset Growth Deceleration, Trims Price Target to $90 on Sector Multiple Compression
- Steed Maintains Hold on Balanced Risk-Reward, Cutting Price Target to $80 Despite Solid Q1 Beat and Slight Guidance Raise
- Merit Medical price target lowered to $85 from $90 at Canaccord
- Merit Medical Earnings Call Highlights Growth Amid Headwinds
- Merit Medical Tops Q1 Forecasts, Raises 2026 Outlook